https://orcid.org/0000-0002-2013-0887
References
- Gedeborg R, Lindhagen L, Loeb S, et al. Androgen deprivation therapy, comorbidity, cancer stage and mortality from COVID-19 in men with prostate cancer. Scand J Urol. 2021.
- Gedeborg R, Styrke J, Loeb S, et al. Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemic. PLOS One. 2021;16(10):e0255966.
- Caffo O, Messina M, Veccia A, et al. Severe acute respiratory syndrome coronavirus 2 infection in patients with prostate cancer: a critical review. Crit Rev Oncol Hematol. 2021;167:103491.
- Schmidt AL, Tucker MD, Bakouny Z, et al. Association between androgen deprivation therapy and mortality among patients with prostate cancer and COVID-19. JAMA Netw Open. 2021;4(11):e2134330–e2134330.
- Welén K, Rosendal E, Gisslén M, et al. A phase 2 trial of the effect of antiandrogen therapy on COVID-19 outcome: No evidence of benefit, supported by epidemiology and in vitro data. European Urology. 2021. doi:https://doi.org/10.1016/j.eururo.2021.12.013.
- Ghazizadeh Z, Majd H, Richter M, et al. Androgen regulates SARS-CoV-2 receptor levels and is associated with severe COVID-19 symptoms in men. bioRxiv. 2020.doi:https://doi.org/10.1101/2020.05.12.091082.
- Auerbach JM, Khera M. Testosterone's role in COVID-19. J Sex Med. 2021;18(5):843–848.
- Welen K, Overby AK, Ahlm C, et al. COVIDENZA – a prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial. Trials. 2021;22(1):209.
- McCoy J, Goren A, Cadegiani FA, et al. Proxalutamide reduces the rate of hospitalization for COVID-19 male outpatients: a randomized double-blinded placebo-controlled trial. Front Med. 2021;8:668698.
- Nickols NG, Goetz MB, Graber CJ, et al. Hormonal intervention for the treatment of veterans with COVID-19 requiring hospitalization (HITCH): a multicenter, phase 2 randomized controlled trial of best supportive care vs best supportive care plus degarelix: study protocol for a randomized controlled trial. Trials. 2021;22(1):431.